News & Events
News & Events
January 8, 2019
Flinn Foundation Awards Critical Path Institute and TGen North a New Grant to Develop and Pilot a System to Respond to Antimicrobial ResistanceTUCSON, Ariz., January 8, 2019 — Critical Path Institute (C-Path) and Flagstaff, Arizona-based TGen North — the Pathogen and Microbiome Division of the Translational Genomics Research Institute (TGen) — have received a Phase 1 Concept Validation grant from the Flinn Foundation, of $400,000 over 12 months, to develop and pilot a framework enabling the state...
January 4, 2019
At the IBD Biomarker Summit, Hosted by the Crohn’s & Colitis Foundation, C-Path Shares the Case for formation of an IBD Biomarker ConsortiumAt the IBD Biomarkers Summit, hosted by the Crohn’s & Colitis Foundation on October 17-18, 2018, in Newark, N.J., Critical Path Institute (C-Path) highlighted the need for an Inflammatory Bowel Disease (IBD) focused consortium with the goal to qualify biomarkers as tools to support IBD drug development programs. The two-day participatory event featured presentations and...
December 21, 2018
C-Path Board Member Paula Olsiewski Honored as AAAS 2018 Elected FellowPaula Olsiewski, Ph.D., program director at the Alfred P. Sloan Foundation and Critical Path Institute board member, was named a 2018 Fellow in the Section on Chemistry by the American Association for the Advancement of Science (AAAS). Election as an AAAS Fellow is an honor bestowed upon AAAS members by their peers, and is presented...
December 19, 2018
In Recognition of 10th Anniversary, Raymond Woosley and Janet Woodcock Address CPAD Consortium’s 2018 Annual Meeting and Regulatory Science WorkshopAt its 10th Annual Meeting and Regulatory Science Workshop, November 13, 2018, in Bethesda, MD, C-Path’s Critical Path for Alzheimer’s Disease (CPAD) consortium hosted key stakeholders who gathered to review the progress made made over the past year and identify and prioritize regulatory science needs for Alzheimer disease (AD) and related dementias. At the meeting,...
December 18, 2018
Critical Path Institute Encouraged by FDA to Move Forward on Type 1 Diabetes Biomarker InitiativeBiomarker potentially could identify individuals at risk of developing T1D TUCSON, Ariz., December 18, 2018 — Critical Path Institute (C-Path) announced today that its Type 1 Diabetes (T1D) Consortium has received a positive response to its Letter of Intent (LOI) from the U.S. Food and Drug Administration (FDA) detailing the FDA’s decision to accept the...